

## ADDENDUM TO FINAL STATEMENT OF REASONS AND UPDATED INFORMATIVE DIGEST

### SUMMARY AND RESPONSE TO COMMENTS RECEIVED DURING THE 15-DAY PUBLIC COMMENT PERIOD OF AUGUST 2, 2019 THROUGH AUGUST 16, 2019.

No comments were received during the 15-day public comment period of August 2, 2019 through August 16, 2019.

### SUMMARY AND RESPONSE TO COMMENTS RECEIVED AT THE AUGUST 22, 2019 HEARING FOR ADOPTION.

No comments were received at the August 22, 2019 hearing for adoption.

### UPDATED INFORMATIVE DIGEST/UPDATE TO INITIAL STATEMENT OF REASONS

The proposed text of Rule 1844 was modified to change subsection 1844(g). The text was made available pursuant to Government code section 11346.8(c) and 1 CCR section 44. Subparagraph 1844(g) currently states that the official blood test samples shall not contain any of the drug substances, or their metabolites or analogs listed in subsection (e)(1) to (6) and (e)(8) to (11). However, the proposed amendment removed clenbuterol from subsection 1844(e), which meant that the subsections referred to in subsection 1844(g) should have been renumbered to agree with subsection 1844(e). To correct the text, subsection 1844(g) was changed to read: "Official blood test samples shall not contain any of the drug substances, or their metabolites or analogs listed in subsection (e)(1) to (5) and (e)(7) to (10)."